Outcomes of patients with unresectable stage III non-small cell lung cancer treated with durvalumab and subsequent therapies after disease progression
| Autor: | Damaal Walker, Katerine Dumais, Franco Adjei-Baffour Dickson, Herman W. Powery, Luis E. Raez |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 39:e20531-e20531 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2021.39.15_suppl.e20531 |
| Popis: | e20531 Background: The PACIFIC trial demonstrated that durvalumab improved 3-year overall survival in unresectable Stage III non-small-cell lung cancer (NSCLC) following chemoradiotherapy (CRT). However, there is no consensus on the preferred therapy after patients progress on durvalumab. This study aimed to determine the real-world outcomes of patients treated with durvalumab and subsequent therapies after disease progression. Methods: Forty-five NSCLC patients previously treated in a large multi-site community cancer center with concurrent CRT followed by durvalumab were evaluated for progression-free survival (PFS). Subsequent lines of therapy for patients who progressed on durvalumab were also evaluated. Treatment characteristics of the patients were also reviewed. PFS was reported using the Kaplan-Meier method using a p-value of < 0.05 for statistical significance. Results: Baseline characteristics of patients included a median age of 65 years (46-90), 99% with ECOG 0 or 1, and 89% with PDL-1>50%. The median duration between the end of CRT and initiation of durvalumab was 1.3 months and the median treatment duration was 8.1 months the A total of 13 patients (29%) progressed on durvalumab; the 12-month PFS was 65.9% (49-79.7) and the 18-month PFS was 59.1% (36.7-76.1). The median PFS observed was 38.4 months (Table 1). The subsequent lines of therapy for the 14 patients that progressed were as follows: 8(62%). immunotherapy/chemotherapy combination, 2(15%) chemotherapy only, 2(15%) targeted therapy, and 1(8%) radiation therapy. Conclusions: Evaluation of consolidation durvalumab in patients with locally advanced NSCLC finds PFS in clinical practice to be consistent with trial data. Subsequent lines of therapy were consistent with guideline recommendations for newly diagnosed stage IV NSCLC. Longer follow-up will be needed to determine the PFS associated with the different subsequent therapies and how immunotherapy failure could potentially affect outcomes of subsequent chemo/immunotherapy combinations.[Table: see text] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|